Last Updated: November 16, 2026

Investigational Drug Information for Norketotifen

« Back to Dashboard


What is the development status for investigational drug Norketotifen?

Norketotifen is an investigational drug.

There have been 4 clinical trials for Norketotifen. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2019.

The most common disease conditions in clinical trials are Influenza, Human, Conjunctivitis, Allergic, and Rhinitis, Allergic. The leading clinical trial sponsors are Emergo Therapeutics, Inc. and [disabled in preview].

There are forty-six US patents protecting this investigational drug and one hundred and one international patents.

Recent Clinical Trials for Norketotifen
TitleSponsorPhase
Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like IllnessEmergo Therapeutics, Inc.Phase 2
Norketotifen for the Treatment of Uncomplicated Influenza-like IllnessEmergo Therapeutics, Inc.Phase 2
Efficacy and Safety of Norketotifen in Adults With Allergic RhinitisEmergo Therapeutics, Inc.Phase 2

See all Norketotifen clinical trials

Clinical Trial Summary for Norketotifen

Top disease conditions for Norketotifen
Top clinical trial sponsors for Norketotifen

See all Norketotifen clinical trials

US Patents for Norketotifen

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Norketotifen ⤷  Start Trial Anti-allergy benzocycloheptathiophene derivatives Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd (Fujian, CN) ⤷  Start Trial
Norketotifen ⤷  Start Trial Compositions for the treatment of cataracts Catacore, Inc. (West Richland, WA) ⤷  Start Trial
Norketotifen ⤷  Start Trial Mast cell stabilizers for treatment of hypercytokinemia and viral infection Emergo Therapeutics Inc ⤷  Start Trial
Norketotifen ⤷  Start Trial Mast cell stabilizers for treatment of hypercytokinemia and viral infection Emergo Therapeutics Inc ⤷  Start Trial
Norketotifen ⤷  Start Trial Methods of treatment of asthma and COPD Bridge Pharma Inc ⤷  Start Trial
Norketotifen ⤷  Start Trial Mast cell stabilizers for treatment of fever Emergo Therapeutics Inc ⤷  Start Trial
Norketotifen ⤷  Start Trial Triamcinolone and moxifloxacin compositions Somerset Therapeutics LLC ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Norketotifen

Drugname Country Document Number Estimated Expiration Related US Patent
Norketotifen China CN103619839 2031-06-28 ⤷  Start Trial
Norketotifen European Patent Office EP2727919 2031-06-28 ⤷  Start Trial
Norketotifen Japan JP2014526438 2031-06-28 ⤷  Start Trial
Norketotifen Japan JP5978296 2031-06-28 ⤷  Start Trial
Norketotifen World Intellectual Property Organization (WIPO) WO2013000406 2031-06-28 ⤷  Start Trial
Norketotifen Australia AU2016298951 2035-07-27 ⤷  Start Trial
Norketotifen Canada CA2993196 2035-07-27 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.